Connect with us

Health and Wellness

No, taking drugs like Ozempic is not a “cheat” on weight loss or an “easy way out”

Published

on


Effective drugs for obesity have been available for a very long time. Administer semaglutide (sold as Ozempic and Wegovy), which helps people improve weight-related health, including risk reduction heart attack or stroke while reducing the noise related to eating.

As the demand for semaglutide increases, so does claims that taking it is “cheating” on weight loss or the “easy way out.”

We don’t tell individuals who need statins to treat high cholesterol or drugs to regulate hypertension that they’re cheating or taking the simple way out.

We also needs to not shame people taking semaglutide. It is a medication used to treat diabetes and obesity that have to be used long-term and has risks and unwanted side effects in addition to advantages. Prescribed to treat obesity, it is given alongside advice on food regimen and exercise.



How it’s working?

Semaglutide is glucagon-like peptide-1 receptor agonist (GLP-1RA). This implies that the body produces its own glucagon-like peptide-1 hormone, the so-called GLP-1 briefly, work higher.

When this happens, GLP-1 is secreted by intestinal cells detects increased nutrient levels after a meal. This stimulates the production of insulin, which lowers blood sugar levels.

GLP-1 also slows gastric emptying, which causes a feeling of satiety and reduces hunger and the sensation of reward after eating.

GLP-1 receptor agonist (GLP-1RA) drugs corresponding to Ozempic improve the motion of the body’s own GLP-1 by mimicking and prolonging its effects.

Some studies have shown that less GLP-1 is released after meals adults with obesity or type 2 diabetes in comparison with adults with normal glucose tolerance. So less GLP-1 circulating in your blood means you do not feel as full after eating and feel hungry again more quickly in comparison with individuals who produce more.

GLP-1 has a very short half-life of approx two minutes. Therefore, GLP-1RA drugs are designed to have a very long half-life of approx seven days. Therefore, semaglutide is given as a weekly injection.



What can users expect? What does the research say?

Higher doses of semaglutide are prescribed for the treatment of obesity in comparison with the treatment of type 2 diabetes (as much as 2.4 mg vs. 2.0 mg per week).

An enormous group randomized, controlled trialscalled the STEP studies, all tested weekly injections of two.4 mg of semaglutide compared with various interventions or placebo medications.

Weekly injections of semaglutide 2.4 mg were consistently present in studies lasting 1.3–2 years. led to six–12% greater weight loss in comparison with placebo or alternative interventions. The mean change in body weight depended on the duration of treatment and the length of the statement period.

Higher doses of semaglutide are prescribed for obesity than for type 2 diabetes.
fcm82/Shutterstock

Weight loss attributable to semaglutide also results in: lowering systolic and diastolic blood pressure by roughly 4.8 mmHg and a couple of.5 mmHg, respectively, which suggests a reduction triglyceride levels (a sort of fat within the blood) i improvement of physical functions.

Another recent study in adults with pre-existing heart disease and obesity but without type 2 diabetes found that adults receiving weekly injections of semaglutide 2.4 mg 20% less risk specific cardiovascular events, including nonfatal heart attack, stroke, or death from heart problems, after three years of follow-up.

Who is eligible for semaglutide?

Australia’s regulator, the Therapeutic Goods Administration (TGA), did so approved semaglutide, sold under the name Ozempic, for the treatment of type 2 diabetes.

However, as a result of shortages, the TGA has advised doctors not to prescribe the brand new Ozempic medicines for off-label use, for instance for the treatment of obesity, and the Pharmaceutical Benefits Scheme does not currently subsidize the medication’s off-label use.

TGA has approved Wegovy for the treatment of obesity but is currently not available in Australia.



Once available, doctors will have the option to prescribe the drugs semaglutide used to treat obesity combined with lifestyle interventions (including food regimen, physical activity and psychological support) in adults with obesity (BMI 30 or more) or individuals with a BMI of 27 or more who even have weight-related health complications.

What else must you remember during Ozempic treatment?

Checking details regarding Intervention components of the STEP trialyou possibly can see that the participants put a lot of effort and time. In addition to taking medications, in most studies participants attended short lifestyle counseling sessions with dietitians or other health care professionals a minimum of every 4 weeks.

The support sessions were designed to assist people stick with consuming 2,000 kilojoules (500 calories) less of their energy needs and doing 150 minutes of exercise each day. moderate or intense physical activitylike a brisk walk, dancing and gardening every week.

The STEP studies varied in other elements, with follow-up periods starting from 68 to 104 weeks. The purpose of this study was to show the impact of adding the drug to other lifestyle advice.

A woman takes a break while exercising
Study participants also exercised for 150 minutes a week.
Elena Nichizhenova/Shutterstock

AND review of obesity drug research found that individuals reported needing less cognitive behavior training to assist them maintain their reduced energy intake. This is one aspect where drug treatment may make compliance somewhat easier. Not feeling hungry and “turning off” environmental cues to eating may mean less support in setting goals, self-monitoring food intake, and avoiding things that trigger eating.

But what are the unwanted side effects?

Semaglutide unwanted side effects switch on nausea, diarrhea, vomiting, constipation, indigestion and abdominal pain.

In one study these caused drug discontinuation in 6% of individuals, but interestingly also in 3% of individuals taking placebo.

More serious unwanted side effects included gallbladder disease, acute pancreatitis, hypoglycemia, acute kidney disease, and injection site reactions.



To reduce the danger or severity of unwanted side effects, Drug doses are increased very slowly for months. Studies indicate that after full dose and response is achieved, it must be used long-term.

Given this long-term commitment and related high out-of-pocket drug costsrelating to taking semaglutide to treat obesity, it could actually certainly not be considered a “scam”.


This article was originally published on : theconversation.com
Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health and Wellness

Jury awarded $310 million to parents of teenager who died after falling on a ride at Florida amusement park – Essence

Published

on

By

Sun Sentinel/Getty Images

The family of Tire Sampson, the 14-yr-old who tragically died on an amusement park ride in Orlando, Florida, in 2022, has been awarded $310 million in a civil lawsuit.

Tire, who was visiting ICON Park along with his family on March 24, 2022, fell from the FreeFall drop tower. Although he was taken to a nearby hospital, he didn’t survive his injuries.

Now, greater than two years later, a jury has held the vehicle manufacturer, Austria-based Funtime Handels, responsible for the accident and awarded the Tire family $310 million. According to reports from local news stations WFTV AND KSDKthe jury reached its verdict after about an hour of deliberation.

Tyre’s parents will each receive $155 million, according to attorney spokesman Michael Haggard.

Attorneys Ben Crump and Natalie Jackson, who represented Tyre’s family, shared their thoughts on this landmark decision via X (formerly Twitter). “This ruling is a step forward in holding corporations accountable for the safety of their products,” they said in a statement.

Lawyers stressed that Tyre’s death was attributable to “gross negligence and a failure to put safety before profits.” They added that the ride’s manufacturer had “neglected its duty to protect passengers” and that the substantial award ensured it could “face the consequences of its decisions.”

Crump and Jackson said they hope the result will encourage change throughout the theme park industry. “We hope this will spur the entire industry to enforce more stringent safety measures,” they said. “Tire heritage will provide a safer future for drivers around the world.”

An investigation previously found that Tyre’s harness was locked through the descent, but he dislodged from his seat through the 430-foot fall when the magnets engaged. Tire’s death was ruled the result of “multiple injuries and trauma.”

ICON Park said at the time that it could “fully cooperate” with the authorities.

This article was originally published on : www.essence.com
Continue Reading

Health and Wellness

Tireless HIV/AIDS advocate A. Cornelius Baker dies

Published

on

By

HIV/AIDS Advocate, A. Cornelius Baker


A. Cornelius Baker, a tireless advocate of HIV and AIDS testing, research and vaccination, died Nov. 8 at his home in Washington, D.C., of hypertensive, atherosclerotic heart problems, in response to his partner, Gregory Nevins.

As previously reported, Baker was an early supporter for people living with HIV and AIDS within the Nineteen Eighties, when misinformation and fear-mongering in regards to the disease were rampant.

According to Douglas M. Brooks, director of the Office of National AIDS Policy under President Obama, it was Baker’s Christian faith that guided him toward compassion for others.

“He was very kind, very warm and inclusive – his circles, both professional and personal, were the most diverse I have ever seen, and he was guided by his Christian values,” Brooks told the outlet. “His ferocity was on display when people were marginalized, rejected or forgotten.”

In 1995, when he was executive director of the National AIDS Association, Baker pushed for June 27 to be designated National HIV Testing Day.

In 2012, he later wrote on the web site of the Global Health Advisor for which he was a technical advisor that: “These efforts were intended to help reduce the stigma associated with HIV testing and normalize it as part of regular screening.”

https://twitter.com/NBJContheMove/status/1856725113967632663?s=19

Baker also feared that men like himself, black gay men, and other men from marginalized communities were disproportionately affected by HIV and AIDS.

Baker pressured the Clinton administration to incorporate black and Latino people in clinical drug trials, and in 1994 he pointedly told the Clinton administration that he was bored with hearing guarantees but seeing no motion.

According to Lambda Legal CEO Kevin Jennings, yes that daring attitude that defines Baker’s legacy in the world of ​​HIV/AIDS promotion.

“Cornelius was a legendary leader in the fight for equality for LGBTQ+ people and all people living with HIV,” Jennings said in a press release. “In the more than twenty years that I knew him, I was continually impressed not only by how effective he was as a leader, but also by how he managed to strike the balance between being fierce and kind at the same time. His loss is devastating.”

Jennings continued: “Cornelius’ leadership can’t be overstated. For many years, he was one in all the nation’s leading HIV/AIDS warriors, working locally, nationally and internationally. No matter where he went, he proudly supported the HIV/AIDS community from the Nineteen Eighties until his death, serving in various positions including the Department of Health and Human Services, the National Association of Persons with Disabilities AIDS, and the Whitman-Walker Clinic . Jennings explained.

Jennings concluded: “His career also included several honors, including being the first recipient of the American Foundation for AIDS Research Foundation’s organization-building Courage Award. Our communities have lost a pillar in Cornelius, and as we mourn his death, we will be forever grateful for his decades of service to the community.”

Kaye Hayes, deputy assistant secretary for communicable diseases and director of the Office of Infectious Diseases and HIV/AIDS Policy, in her comment about his legacy, she called Baker “the North Star.”.

“It is difficult to overstate the impact his loss had on public health, the HIV/AIDS community or the place he held in my heart personally,” Hayes told Hiv.gov. “He was pushing us, charging us, pulling us, pushing us. With his unwavering commitment to the HIV movement, he represented the north star, constructing coalitions across sectors and dealing with leaders across the political spectrum to deal with health disparities and advocate for access to HIV treatment and look after all. He said, “The work isn’t done, the charge is still there, move on – you know what you have to do.” It’s in my ear and in my heart in the case of this job.

Hayes added: “His death is a significant loss to the public health community and to the many others who benefited from Cornelius’ vigilance. His legacy will continue to inspire and motivate us all.”

Baker is survived by his mother, Shirley Baker; his partner Nevins, who can be senior counsel at Lambda Legal; his sisters Chandrika Baker, Nadine Wallace and Yavodka Bishop; in addition to his two brothers, Kareem and Roosevelt Dowdell; along with the larger HIV/AIDS advocacy community.


This article was originally published on : www.blackenterprise.com
Continue Reading

Health and Wellness

Bovaer is added to cow feed to reduce methane emissions. Does it pass into milk and meat? And is it harmful to humans?

Published

on

By

There are growing concerns in regards to the use of feed supplements, Bowar 10to reduce methane production in cows.

Bovaer 10 consists of silicon dioxide (mainly sand), propylene glycol (food stabilizer approved by Food Safety Australia New Zealand) and lively substance 3-nitrooxypropanol (3-NOP).

There has been an enormous amount of misinformation in regards to the safety of 3-NOP, with some milk from herds fed this additive being labeled “Frankenmilk”. Others feared it could get to humans through beef.

The most significant thing is that 3-NOP is secure. Let’s clear up some major misconceptions.

Why do we want to limit methane production?

In our attempts to limit global warming, we’ve placed the best emphasis on CO₂ because the major man-made greenhouse gas. But methane is also a greenhouse gas, and although we produce less of it, it is: a much stronger greenhouse gas than CO₂.

Agriculture is the largest a man-made source of methane. As cattle herds expand to meet our growing demand for meat and milk, reducing methane production from cows is a vital way to reduce greenhouse gas emissions.

There are several ways to do that. Stopping bacteria within the stomachs of cows that produce methane one approach is to produce methane.

The methane produced by cows and sheep doesn’t come from the animals themselves, but from the microbes living of their digestive systems. 3-NO stop the enzymes that perform the last step of methane synthesis in these microorganisms.

3-NOP is not the one compound tested as a feed additive. Australian product based on seaweed, Rumin8for instance, it is also in development. Saponins, soap-like chemicals present in plants, and essential oils as well has been examined.

However, 3-NOP is currently one of the popular effective treatments.

Nitrooxypropanol structure: red balls are oxygen, gray carbon, blue nitrogen and white hydrogen.
PubChem

But is not it poison?

There are concerns on social media that Bovaer is “poisoning our food.”

But, as we are saying in toxicology, it’s the dose that makes the poison. For example, arsenic is deadly 2–20 milligrams per kilogram of body weight.

In contrast, 3-NOP was not lethal on the doses utilized in safety studies, up to 600 mg 3-NOP per kg body weight. At a dose of 100 mg per kg body weight in rats, it didn’t cause any adversarial effects.

What about reproductive issues?

The effect of 3-NOP on the reproductive organs has generated numerous commentary.

Studies in rats and cows showed that doses of 300–500 mg per kg body weight caused: contraction of the ovaries and testicles.

In comparison, to achieve the identical exposure in humans, a 70 kg human would want to eat 21–35 grams (about 2 tablespoons) of pure 3-NOP every day for a lot of weeks to see this effect.

No human will likely be exposed to this amount because 3-NOP doesn’t pass into milk – is fully metabolized within the cow’s intestines.

No cow will likely be exposed to these levels either.

The cow licks itself
Cows will not be exposed to levels tested on animals in laboratory studies.
Ground photo/Shutterstock

What about cancer?

3-NOP is not genotoxic or mutagenicwhich implies it cannot damage DNA. Thus, the results of 3-NOP are dose-limited, meaning that small doses will not be harmful, while very high doses are (unlike radiation where there is no secure dose).

Scientists found that at a dose of 300 mg per kilogram of body weight benign tumors of the small intestine of female ratsbut not male rats, after 2 years of every day consumption. At a dose of 100 mg 3-NOP per kg body weight, no tumors were observed.

Cows eat lower than 2 grams of Bovaer 10 per day (of which only 10% or 0.2 grams is 3-NOP). This is about 1,000 times lower than the appropriate every day intake 1 mg 3-NOP per kg body weight per day for a cow weighing 450 kg.

This level of consumption will likely be not the result in cancer or any of them other adversarial effects.

So how much are people exposed to?

Milk and meat consumers will likely be exposed to zero 3-NOP. 3-NOP doesn’t penetrate milk and meat: is completely metabolized within the cow’s intestines.

Farmers could also be exposed to small amounts of the feed additive, and industrial employees producing 3-NOP will potentially be exposed to larger amounts. Farmers and industrial employees already wear personal protective equipment to reduce exposure to other agricultural chemicals – and it is advisable to do that with Bovear 10 as well.

Milk
3-NOP doesn’t penetrate milk and meat.
Shutterstock

How widely has it been tested?

3-NOP has been in development for 15 years and has been subject to multiple reviews by European Food Safety Authority, UK Food Safety Authority AND others.

It has been extensively tested over months of exposure to cattle and has produced no unintended effects. Some studies actually say so improves the standard of milk and meat.

Bovaer was approved for use in dairy cattle by the European Union from 2022 and Japan in 2024. It is also utilized in many other countries, including: in beef products, amongst others Australia.

A really small amount of 3-NOP enters the environment (lower than 0.2% of the dose taken), no accumulates and is easily decomposed subsequently, it doesn’t pose a threat to the environment.

Since humans will not be exposed to 3-NOP through milk and meat, long-term exposure is not an issue.

What does Bill Gates have to do with this?

Bill Gates has invested in a distinct feed processing method for methane, Australian seaweed-based Rumin8. But he has nothing to do with Bovaer 10.

The Bill & Melinda Gates Foundation awarded research grants to the corporate producing 3-NOP for malaria control researchnot for 3-NOP.

The bottom line is that adding 3-NOP to animal feed doesn’t pose any risk to consumers, animals or the environment.

This article was originally published on : theconversation.com
Continue Reading
Advertisement

OUR NEWSLETTER

Subscribe Us To Receive Our Latest News Directly In Your Inbox!

We don’t spam! Read our privacy policy for more info.

Trending